Chemotherapy for low-grade glioma: When, for whom, which regimen?

Current Opinion in Neurology

Volumn 28, Issue 6, 2015, Pages 633-638

  Van Den Bent, Martin J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy; Low grade glioma; PCV; Temozolomide; Treatment

Indexed keywords

CARMUSTINE; LOMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANAPLASTIC GLIOMA; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; DRUG TOLERABILITY; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LONG TERM SURVIVAL; LOW RISK PATIENT; MOLECULAR DIAGNOSIS; MONOTHERAPY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; CHEMORADIOTHERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; GLIOMA; HUMANS;

EID: 84947491421     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000257     Document Type: Review

References (31)

1. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 2014; 32:5s.
2. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31:337-343.
3. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31:344-350.
4. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomus-tine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874-5880.
5. Chang SM, Zhang P, Cairncross JG, et al. Results of NRG oncology/RTOG 9813 A phase III randomized study of radiation therapy (RT) and temozolo-mide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astro-cytoma (AA). J Clin Oncol 2015; 33 (Suppl); abstr 2002.
6. Baumert B, Hegi M, Mason W, et al. Radiotherapy in relation to temozolomide: subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma. J Clin Oncol 2015; 33 (Suppl); abstr 2006.
7. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012; 30:3065-3070.
8. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 2006; 24:2715-2722.
9. Cairncross JG, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligoden-droglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 2006; 24:2707-2714.
10. Wick W, Roth P, Wiestler B, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 2015; 33 (Suppl); abstr 2001.
11. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet 2002; 360:1361-1368.
12. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009; 8:810-818.
13. Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol 2014; 32:535-541.
14. Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoas-trocytoma survivors. J Neurooncol 2014; 116:161-168.
15. Taal W, van der Rijt CC, Dinjens WN, et al. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. J Neurooncol 2015; 121:365-372.
16. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010; 120:297-304.
17. Cancer Genome Atlas Research Network. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481-2498.
18. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014; 128:561-571.
19. Labussiere M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 2014; 111:2024-2032.
20. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32:783-790.
21. van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendro-gliomas and oligoastrocytomas: a report from EORTC study 26951. Clin Cancer Res 2013; 19:5513-5522.
22. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81:1515-1522.
23. Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015; 129:585-596.
24. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 2008; 109:835-841.
25. Baumert BG, Mason WP, Ryan G, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol 2015; 31 (Suppl); abstr 2007.
26. Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis ofEORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol 2013; 15:1568-1579.
27. Levin VA, Silver P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy and CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiation Oncol Biol Phys 1990; 18:321-324.
28. Prados MD, Scott C, Curran WJ, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation oncology group protocols comparing survival with carmus-tine or PCV adjuvant chemotherapy. J Clin Oncol 1999; 17:3389-3395.
29. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011; 13:649-659.
30. Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47:458-468.
31. Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014; 5:1515-1525.